MétaCan
Menu
Retour à la cohorte
Enregistrement W3047975909 · doi:10.1097/mat.0000000000001250

Summary of the 2020 IFAO-ASAIO Session on Implantable Artificial Kidney

2020· article· en· W3047975909 sur OpenAlexaboutno aff
Stephen R. Ash, Thomas Groth, Fokko P. Wieringa

Notice bibliographique

RevueASAIO Journal · 2020
Typearticle
Langueen
DomaineMedicine
ThématiqueOrgan Donation and Transplantation
Établissements canadiensnon disponible
Organismes subventionnairesnon disponible
Mots-clésGeneral partnershipSession (web analytics)Renal replacement therapyMedicineGovernment (linguistics)Round tablePolitical scienceBusinessSurgeryLaw

Résumé

récupéré en direct d'OpenAlex

For the 2020 meeting of ASAIO (American Society for Artificial Internal Organs), the International Federation for Artificial Organs (IFAO) planned a special session on the implantable artificial kidney (IAK) and the Kidney Implant Developers NEtwork Worldwide “KIDNEW.” This session was in response to a request from Murray Sheldon, MD, of the FDA, on behalf of the Kidney Health Initiative (KHI). KHI is a public-private partnership that has expanded to include over 100 companies and organizations representing patients, care partners, health care professionals, industry, and government. A major goal of KHI is to encourage innovation in the treatment of patients with end-stage renal disease, especially with radically new approaches that go far beyond the standard peritoneal or hemodialysis used widely today. A renal replacement therapy (RRT) Roadmap has been created by KHI to encourage innovative approaches to RRT to address patients’ needs.1 Although this roadmap is “agnostic” to the final form of RRT, the goal of an IAK is one of the most attractive eventual therapies and a recurrent subject of presentations at ASAIO. With the assistance of Dr Sheldon and Fokko Wieringa, PhD, a list was created of many of the laboratories around the world that have focused on projects related to or directly leading toward a workable IAK. Dr Ash sent out invitations, and from the response, an impressive program was created (Table 1). Table 1. - Program of the ASAIO-IFAO Session on IAK and “KIDNEW” An International Roadmap for Innovative Renal Replacement Therapy, Murray Sheldon, FDA, United States The Kidney Project, Shuvo Roy, UCSF, United States Development of New Artificial Kidney Technology, Jamie Hestekin, US Kidney Research Corporation, UCLA and University of Arkansas, United States Ambulatory Kidney to Improve Vitality (AKTIV), Buddy Ratner, Center for Dialysis Innovation, University of Washington, United States The (Re)building a Kidney Consortium, Iain Drummond, Mount Desert Island Biological Lab, United States Implantable Blood Purification Devices, Morteza Ahmadi, Qidni, Canada Membranes for (Bio)Artificial Kidney Devices, Dimitrios Stamatialis, University of Twente, the Netherlands Regenerative Medicine Crossing Borders, RegMed XB: The Kidney Moonshot, Marianne Verhaar, Utrecht University of Medical Center, the Netherlands Update on NeoKidney Consortium & KIDNEW, Fokko Wieringa, IMEC, and Dutch Kidney Foundation Experiences from Semiconductor Roadmapping and Getting Disruptive Medical Technology Running Patrick de Jager, ASML, the Netherlands Wrap-up Discussion and Action Points, led by Steve Ash, Fokko Wieringa, and Murray Sheldon ASAIO, American Society for Artificial Internal Organs; IAK, implantable artificial kidney; IFAO, International Federation for Artificial Organs; KIDNEW, Kidney Implant Developers NEtwork Worldwide. Due to the COVID-19 epidemic, the in-person ASAIO meeting for 2020 was canceled. ASAIO abstract presentations were taped by the speakers, using PowerPoint slides with audio description. These presentations are now available with a modest registration fee, through the ASAIO.org website. The IFAO and the organizers of the IAK “KIDNEW” session, however, decided to hold a truly interactive session, with speakers presenting in real time and with live audio questions and additional audience feedback recorded in text via a chatbox. The IAK “KIDNEW” session was held on June 12, the same day that the in-person session had been scheduled. Technical hosting of the session was kindly provided by IMEC, in Eindhoven, the Netherlands. Drs Sheldon and Wieringa were cochairs. Members of ASAIO, European Society for Artificial Organs (ESAO), Japanese Society of Artificial Organs (JSAO), and KHI comprised the audience, as well as speakers and audience from a virtual European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA) sister-session regarding advances in RRT, which was held 3 days earlier on June 9. Both sessions were advertised jointly throughout the organizational networks of ASAIO, ESAO, JSAO, IFAO, KHI, ERA-EDTA, and European Kidney Health Alliance. The presented combined progress was truly remarkable and showed tremendous potential. Dr Sheldon opened the session with a pledge to consider “coopetition” as an approach to speed-up the RRT innovation roadmap, which is also described in a recent article in Artificial Organs.2 The speakers at the session presented impressive new technologies for solving the numerous challenges of making an IAK capable of providing long-term and effective removal of uremic toxins: Dr Shuvo Roy showed impressive results with hemofilters made from silicon wafers, successfully implanted in pigs with 90% patency up to 30 days, plus a working cell-based bioreactor, functioning 3 days in a pig without inducing an immune reaction! Dr Jamie Hestekin showed a modular WAK design (to be miniaturized to IAK) using electrically steerable selective removal of Na+, Mg2+, K+, or Ca2+ ions by electrodeionization, as well as selective removal of glucose by nanofiltration, and selective water transport by reverse osmosis. Dr Buddy Ratner amazed with selective photocatalytic oxidation of urea using TiO2 nanowires and STAR-polymer material that produces no foreign body reaction and is fully symbiotic with human tissue, which enables vascular grafts with unprecedented low infection rates. Dr Iain Drummond updated upon impressive progress made by the (Re)building a kidney consortium on cell lines, organoids, three-dimensional-printing of nephron structures, and a great data hub while calling his role in the consortium as “the plumber” that connects all components. Dr Morteza Ahmadi updated on the Qidni device tested in a pig, which utilizes ultrathin nanoporous silicon membranes and a connection to the bladder. Dr Dimitrios Stamiatalis presented mixed matrix membranes for enhanced removal of protein-bound toxins, as well as selective sorbents for urea and a hollow fiber membrane with living cells embedded. Dr Marianne Verhaar gave an overview of the 250 million Euro Dutch/Belgian research consortium RegMedXB, which works on regenerating tissue with intelligent, life-like materials, like supramolecular materials that offer tunable properties and provide very promising results. RegMedXB also has interesting computational models. Dr Fokko Wieringa provided an overview of the NeoKidney initiative from the Dutch Kidney Foundation (that also supports RegMedXB), the first step on their roadmap is now nearing completion with the launch of NextKidney, but an IAK is the ultimate long-term goal. Dr Patrick De Jager showed us all the great progress made possible by numerous scientists and businesses in “coopetition” bound by an overall roadmap for progress, as for decades has been successful practice within the semiconductor industry, using Moore’s law. He also provided a real-world MedTech example of how he applied these roadmapping processes, resulting in significant investment from a Belgium company to develop and realize production of isotopes for nuclear medicine without a nuclear reactor. The concluding discussion was characterized by a highly cooperative atmosphere. Offers were made to share cell-lines, for follow-up discussions on technical cooperation. The Dutch group in Utrecht needed a “plumber” to connect their cells, and was immediately offered help from the United States and Daniel Gosset from NIH-NIDDK offered to provide an overview of calls for renal innovation, which he promptly did. The list of NIDDK-sponsored programs to improve kidney failure therapy is available at https://asaio.org/multimedia/files/virtual/Proposals.pdf. The entire session, including presentations, audience questions, and speaker responses, was videotaped. The lively two-hour session is available through a link at the ASAIO.org website or directly at https://www.youtube.com/watch?v=Rx5LOwv_qkw&feature=youtu.be. We encourage you to watch the video. All speakers at this IAK “KIDNEW” session have been invited for an update-session during the 2021 ASAIO meeting in Washington, DC. It will be fascinating to see how much progress has been made by these very special and dedicated researchers. The ERA-EDTA sister-event can also be viewed, viahttps://nierstichting.nl/professionals/webinar/.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,003
score de la tête « metaresearch » (Gemma)0,003
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Sans objet · Signal consensuel: Sans objet
GenreSignal candidat: Synthèse · Signal consensuel: aucune
Score de désaccord entre enseignants0,262
Score d'incertitude au seuil0,877

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0030,003
Méta-épidémiologie (sens strict)0,0010,000
Méta-épidémiologie (sens large)0,0010,001
Bibliométrie0,0010,001
Études des sciences et des technologies0,0010,000
Communication savante0,0040,002
Science ouverte0,0010,002
Intégrité de la recherche0,0030,003
Charge utile insuffisante (le modèle a refusé de juger)0,2620,134

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,022
Tête enseignante GPT0,268
Écart entre enseignants0,246 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeSans objet
Domainenon disponible
GenreSynthèse

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations3
Publié2020
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueASAIO JournalMême sujetOrgan Donation and TransplantationTravaux en français237 207